11 results about "Thromboembolic disorder" patented technology

The present application relates to a new use of Veronica longifolia quinone A, and in particular to the use of Veronica longifolia quinone A in the preparation of a drug for preventing or treating thromboembolic diseases. The present application finds that Veronica longifolia quinone A can significantly inhibit the platelet aggregation activity induced by different inducers in vitro: in the thrombus model experiment in vivo, the Veronica longifolia quinone A of the present application can well inhibit the FeCl3-induced carotid artery thrombosis in mice. At the same time, it is found that the Veronica longifolia quinone A of the present application does not have obvious bleeding tendency. It is shown that Veronica longifolia quinone A is expected to play a certain positive role in the prevention or treatment of thromboembolic diseases.

The present invention relates to co-crystals of a compound of formula (I) in which the co-former molecule is succinic acid or citric acid, processes for preparing the co-crystals, pharmaceutical compositions thereof, and methods of treating or preventing thromboembolic disorders using the co-crystals.

The present invention relates to co-crystals of a compound of formula (I) in which the co-former molecule is succinic acid or citric acid, processes for preparing the co-crystals, pharmaceutical compositions thereof, and methods of treating or preventing thromboembolic disorders using the co-crystals.

The present invention provides compounds useful for the treatment or prevention of diseases or conditions involving (a) thromboembolic disorders, (b) inflammatory disorders, or (c) plasma kallikrein activity. [Solution] A compound of formula (I), or its tautomers, stereoisomers, isotope substitutions, or pharmaceutically acceptable salts or solvates is provided. TIFF2026062690000101.tif47128

The invention relates to the technical field of medicines, and finds that a natural product amentoflavone can be used as a GPR35 (G-protein coupled receptor 35, GPR35) receptor agonist and application thereof, the compound is amentoflavone, has GPR35 receptor agonist activity, is a GPR35 receptor agonist, can be used for treating thromboembolic diseases, spring conjunctivitis, intracranial embolism, primary sclerosing cholangitis and myocardial infarction, and can be used for treating various diseases such as thromboembolic diseases, spring conjunctivitis, intracranial embolism, primary sclerosing cholangitis and myocardial infarction. Therefore, a novel GPR35 receptor stimulant seedling compound with a clear action target can be provided for the related diseases.

The present invention is directed to Factor XIa inhibitors, tautomers, stereoisomers, isotopologues, and pharmaceutically acceptable salts and solvates thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and / or prophylaxis of thromboembolic disorders, inflammatory disorders, and diseases or conditions in which plasma kallikrein activity is implicated.

The application discloses a drug-loaded system and a preparation method and application thereof, and belongs to the technical field of medicines. The drug-loaded system is a drug system in which a nano drug-loaded material is carried on a supermolecular engineering modified frozen platelet; the nano drug-loaded material is a drug-loaded nanomaterial modified by a first modifier; the supermolecular engineering modified frozen platelet is a liquid nitrogen quick-frozen activated platelet modified by a second modifier; and the first and second modifiers can be self-assembled and combined. The frozen platelet retains thrombus targeting, and after the supermolecular system is engineered to carry the nano drug system, the targeted delivery and rapid release of drugs to a thrombus site can be realized, the drug-loaded system has high safety and specificity, and therefore has high broad-spectrum and promotion values. The preparation method of the drug-loaded system is simple, and the drug-loaded system can be used for preparing a medicine for treating thromboembolic diseases.

This disclosure provides compounds that are tyrosine kinase inhibitors, in particular Bruton's tyrosine kinase (BTK) inhibitors, and which are therefore useful for the treatment of diseases treatable by BTK inhibition, such as cancer, autoimmune, inflammatory, and thromboembolic diseases. Pharmaceutical compositions containing these compounds and processes for their preparation are also provided.

Disclosed are compounds of Formula (I) to (VIII):or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and R1, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

The present invention relates to methods of treating conditions wherein such treatments comprise the administration of certain mono-and / or bis-nitrosolated propylene glycol, including compositions and formulations thereof, and wherein the administration is administered to a patient in need thereof via intraarterial infusion at a dose of about 0.01 nmol kg-1 min-1 to 3000 nmol kg-1 min-1. The invention also relates to the use of mono-nitrosolated propylene glycol and / or bis-nitrosolated propylene glycol for the treatment of thromboembolic diseases.